HLA class II antigen expression in human papillomavirus-associated cervical cancer.
The observation that tumor cells of some neoplasms display major histocompatibility complex (MHC) class II molecules may be of functional significance, influencing the progression of malignancy by allowing the cancer cells to present antigen to the immune system. In the normal cervix, class II molecules are expressed by columnar but not squamous epithelium. The pattern of MHC class II expression in cervical carcinomas has been documented using immunohistochemical methods. Of 53 cervical squamous carcinomas examined for MHC class II expression, only 17% maintained a negative phenotype characteristic of the epithelium from which they were derived, while the remaining tumors exhibited either uniform (45%) or heterogeneous (38%) expression. Tumor areas which were class II positive also express class II associated invariant chain and the adhesion molecules lymphocyte function antigen 3 and intercellular adhesion molecule 1. The DR, DP, and DQ class II MHC subloci are differentially expressed, suggesting independent regulation. There is a trend for tumors with the uniform class II phenotype to predominantly express DR antigen, whereas tumors of the heterogeneous class II phenotype express with equal frequency either DR or DP antigens dominantly. There is no apparent influence of class II status on lymphocyte infiltration of the tumors. The presence of human papillomavirus 16 DNA in the cervical carcinoma specimens was analyzed by Southern blotting of restriction enzyme digested DNA and no correlation between the presence of human papilloma virus and MHC class II expression was found.
Glew
S S
SS
Cancer Research Campaign Department of Immunology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, United Kingdom.
Duggan-Keen
M
M
Cabrera
T
T
Stern
P L
PL
D000328:Adult; D000368:Aged; D000954:Antigens, Surface / Q000032:analysis; D018968:CD58 Antigens; D002294:Carcinoma, Squamous Cell / Q000276:immunology; D015815:Cell Adhesion Molecules / Q000032:analysis; D002584:Cervix Uteri / Q000276:immunology; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006682:HLA-DP Antigens / Q000032:analysis; D006683:HLA-DQ Antigens / Q000032:analysis; D006684:HLA-DR Antigens / Q000032:analysis; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D000949:Histocompatibility Antigens Class II / Q000032:analysis*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1; D007958:Leukocyte Count; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008562:Membrane Glycoproteins / Q000032:analysis; D008875:Middle Aged; D027383:Papillomaviridae / Q000235:genetics; D010641:Phenotype; D014412:Tumor Virus Infections / Q000150:complications / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000276:immunology*
D000954:Antigens, Surface; D018968:CD58 Antigens; D015815:Cell Adhesion Molecules; D004279:DNA, Viral; D006682:HLA-DP Antigens; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D008562:Membrane Glycoproteins; D018799:Intercellular Adhesion Molecule-1